A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice

Figure 4

CIA06-adjuvanted Greenflu-S reduces the mortality and morbidity of mice upon lethal infection with influenza virus. Mice were immunized twice at a 2-week interval with 0.2, 0.05, or 0.01 μg of nonadjuvanted or adjuvanted Greenflu-S. Control mice were given PBS or CIA06. Four weeks after immunization, mice were challenged with homologous influenza virus and monitored for survival (a) and change in body weight (b) for 15 days. Data shown in (b) are presented as the means that were obtained from each group of mice. Survival data for different mouse groups were analyzed using Kaplan-Meier survival curves and log-rank test. Repeated measures ANOVA followed by Bonferroni’s posttest was used to analyze body weight changes for different mouse groups over time. Symbols and indicate and , respectively, when compared with the group given the nonadjuvanted vaccine.

(a)

(b)